Summary: Traumatic brain injury (TBI), including concussions, affects an estimated 69 million people globally each year, yet approved medical treatments remain limited. A new review from the University of Victoria highlights growing evidence that serotonergic psychedelics—especially psilocybin and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)—may reduce harmful inflammation and promote neuroplasticity after brain trauma, offering a potential path toward improved recovery and reduced long-term psychiatric consequences.
The reviewed research indicates these compounds could help the injured brain rebuild connections, restore adaptive plasticity, and lower the risk of depression, anxiety, and post-traumatic stress disorder (PTSD) that can follow TBI. While additional clinical trials and safety studies are needed, psilocybin and 5-MeO-DMT represent promising candidates for new neurorehabilitation strategies.
Key Facts:
- Global impact: Approximately 69 million people sustain traumatic brain injuries each year due to falls, sports collisions, road accidents, and interpersonal violence.
- Psychedelic potential: Psilocybin and 5-MeO-DMT show preclinical and early clinical evidence for reducing neuroinflammation and enhancing neuroplasticity.
- Psychiatric benefits: These compounds may also lower the incidence or severity of depression, anxiety, and PTSD associated with brain injury.
Source: University of Victoria
Overview of the problem
Concussion and other forms of traumatic brain injury create a cascade of biological responses. An initial inflammatory reaction can help clear debris and begin repair, but when inflammation persists it contributes to oxidative stress, disrupted neurotransmission, cell loss, and impaired neuroplasticity. These processes underlie chronic cognitive deficits and psychiatric disorders that can persist long after the initial injury—sometimes even following mild TBI.
What the review found
Researchers from the Christie Lab at the University of Victoria—Zoe Plummer, Josh Allen, Justin Brand and Brian Christie—together with Leah Mayo (University of Calgary) and Sandy Shultz (Vancouver Island University), synthesized preclinical and clinical studies examining the effects of psilocybin and 5-MeO-DMT on brain injury mechanisms. Their analysis, published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, highlights several converging lines of evidence:
- Both psilocybin and 5-MeO-DMT engage serotonergic signaling pathways (notably 5-HT1A and 5-HT2A receptors) that can modulate inflammation and support synaptic remodeling.
- Psilocybin also interacts with neurotrophic TrkB pathways, while 5-MeO-DMT shows activity at sigma-1 receptors—each linked to neuroprotection and enhanced plasticity in preclinical models.
- Clinical studies of psychedelics for mood and anxiety disorders demonstrate sustained improvements in affective symptoms and cognitive flexibility, outcomes that overlap with rehabilitation goals after TBI.
According to Josh Allen, a UVic postdoctoral fellow and co-author, “A blow to the head triggers inflammation that may initially be reparative, but if it becomes chronic it contributes to persistent deficits in learning, memory, and mood. Treatments that both rein in damaging inflammation and reopen windows of plasticity could help the brain reorganize and recover.”
Brian Christie, director of UVic’s Concussion Lab, adds that classical psychedelics may serve a dual function: dampening harmful immune signaling while promoting the formation of new neural pathways to compensate for damaged networks. These combined effects—together with the capacity of psychedelic-assisted therapy to support psychological integration—may reduce the likelihood of long-term psychiatric illness after TBI.
Safety, limitations, and next steps
The review emphasizes important gaps: rigorous, controlled clinical trials focused specifically on TBI populations are limited; optimal dosing paradigms for neurorehabilitation are not established; and the influence of age, sex, preexisting conditions, and timing after injury on efficacy and safety must be clarified. Nonetheless, the existing data justify further translational and clinical research to evaluate psychedelics as adjunctive tools in TBI care.
Implications for health systems
With millions affected and few effective pharmacotherapies available, interventions that accelerate functional recovery and reduce chronic psychiatric burden could relieve pressure on health-care systems and improve patient quality of life. If validated, psychedelic-assisted approaches might complement rehabilitation therapies by creating biological and psychological conditions more conducive to long-term recovery.
Funding: This research was supported by the Canadian Institutes of Health Research (CIHR) and aligns with the United Nations Sustainable Development Goal No. 3: good health and well-being.
About this neuropharmacology and concussion research news
Author: Heather Walmsley
Source: University of Victoria
Contact: Heather Walmsley – University of Victoria
Image: The image is credited to Neuroscience News
Original Research: Open access. “Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury” by Brian Christie et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry. DOI: 10.1016/j.pnpbp.2025.111448
Abstract summary
Traumatic brain injury (TBI) presents complex acute and chronic challenges, including neuroinflammation, oxidative stress, impaired neuroplasticity, neurotransmitter imbalances, and neuronal loss. Emerging preclinical and clinical evidence suggests that serotonergic psychedelics—psilocybin and 5-MeO-DMT—may address multiple aspects of TBI pathology by promoting neuroplasticity, exerting anti-inflammatory and neuroprotective effects, and improving cognitive and affective outcomes. Mechanistically, these compounds act through overlapping and distinct receptor pathways (5-HT1A, 5-HT2A, TrkB, sigma-1) that can support recovery. The review integrates current findings, examines dosing and safety considerations, and outlines clinical challenges, positioning psilocybin and 5-MeO-DMT as promising candidates for adjunctive treatment in neurorehabilitation following TBI.